RYTM

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Surpass Estimates

Rhythm Pharmaceuticals Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss at Up to Nine Months in Patients with HET Obesity on Setmelanotide at ENDO 2021

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

Rhythm Pharmaceuticals, Inc. Announces Closing of $172.5 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering